B. Riley lowered shares of Apellis Pharmaceuticals (NASDAQ:APLS) from a buy rating to a neutral rating in a research note released on Thursday, Marketbeat.com reports. They currently have $27.00 price objective on the stock.
Several other brokerages have also recently issued reports on APLS. JPMorgan Chase boosted their price target on Apellis Pharmaceuticals from $31.00 to $35.00 and gave the company an overweight rating in a research note on Friday, March 23rd. Zacks Investment Research downgraded shares of Apellis Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, March 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $27.50.
Shares of APLS stock traded up $0.10 during trading on Thursday, hitting $26.69. The company had a trading volume of 30,566 shares, compared to its average volume of 116,403. The company has a current ratio of 27.79, a quick ratio of 27.79 and a debt-to-equity ratio of 0.18. The stock has a market cap of $1,373.67 and a P/E ratio of -7.25. Apellis Pharmaceuticals has a one year low of $12.45 and a one year high of $29.34.
Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Monday, March 19th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.33). analysts forecast that Apellis Pharmaceuticals will post -1.16 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in APLS. American International Group Inc. acquired a new position in Apellis Pharmaceuticals during the fourth quarter valued at approximately $158,000. The Manufacturers Life Insurance Company acquired a new position in shares of Apellis Pharmaceuticals during the fourth quarter worth $186,000. Teachers Advisors LLC acquired a new position in shares of Apellis Pharmaceuticals during the fourth quarter worth $270,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Apellis Pharmaceuticals during the fourth quarter worth $317,000. Finally, TIAA CREF Investment Management LLC acquired a new position in shares of Apellis Pharmaceuticals during the fourth quarter worth $343,000. Institutional investors and hedge funds own 31.26% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Apellis Pharmaceuticals (APLS) Downgraded to “Neutral” at B. Riley” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2018/04/13/apellis-pharmaceuticals-apls-downgraded-to-neutral-at-b-riley.html.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.